Microbot Medical Inc. (NASDAQ:MBOT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $6.6250.

A number of research firms recently commented on MBOT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Loop Capital set a $4.00 target price on Microbot Medical in a research report on Wednesday, June 3rd. HC Wainwright reiterated a “buy” rating on shares of Microbot Medical in a report on Tuesday. Finally, Wall Street Zen raised Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. CTC Alternative Strategies Ltd. acquired a new position in shares of Microbot Medical during the first quarter worth $28,000. American Century Companies Inc. purchased a new stake in Microbot Medical during the 2nd quarter worth approximately $32,000. Zacks Investment Management purchased a new stake in shares of Microbot Medical during the third quarter valued at $33,000. Man Group plc acquired a new position in shares of Microbot Medical in the 4th quarter valued at $35,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Microbot Medical in the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical News Summary

Here are the key news stories impacting Microbot Medical this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Microbot Medical, signaling continued analyst confidence in the stock’s long-term outlook.
• Positive Sentiment: The firm raised estimates for several periods, including FY2026 to $(0.24) from $(0.32) and FY2027 to $(0.25), suggesting a slightly better earnings trajectory than previously expected.
• Neutral Sentiment: HC Wainwright’s updated quarterly forecasts for 2026 and 2027 still call for ongoing losses, which keeps the investment thesis dependent on future execution rather than current profitability.
• Negative Sentiment: Even with the upgrades, the estimates remain deeply negative versus the broader market, and the stock may be under pressure because Microbot Medical is still expected to post losses across the forecast period.

Microbot Medical Stock Performance

MBOT opened at $1.79 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. The stock has a market capitalization of $120.23 million, a price-to-earnings ratio of -6.88 and a beta of 1.04. The company has a fifty day moving average of $1.87 and a 200 day moving average of $2.11. Microbot Medical has a fifty-two week low of $1.60 and a fifty-two week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts forecast that Microbot Medical will post -0.28 earnings per share for the current fiscal year.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.